Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

areholders of both companies, bringing the potential for strengthened sustainability of top-tier EPS growth, attractive free cash flow and enhanced cash returns to shareholders. The combination would provide us with enhanced access to cash that we can use to expand our portfolio and fund M&A to supplement organic growth."

Commenting on the Merger, Susan Kilsby, Chairman of Shire said:

"Shire has a long track record of delivering value for both shareholders and patients. Our growth profile has been accelerated under our new management team who have successfully executed a focused strategy.

We believe that this offer reflects the substantial value that we have already created for Shire's shareholders and the strength of our future prospects. We believe that the combined group represents an exciting fit of two complementary businesses that will create a new market leader in specialty pharmaceuticals with a portfolio of fast growing products, a promising pipeline and enhanced growth prospects."

This summary should be read in conjunction with the full text of the following announcement including the Appendices. The Conditions and certain further terms of the Merger are set out in Appendix I. Appendix II contains bases and sources of certain information contained within this document. Appendix III contains details of the irrevocable undertakings given to New AbbVie. Appendix IV contains the definitions of certain terms used in this announcement.There will be an investor call at 2.00pm BST / 8.00am CST. Dial-in details are set out below:
UK toll free : 0800-279-9630
US toll free : 866-617-1526
International: 001-210-795-0624
Passcode: AbbVie

Further informationThis announcement is provided for informational purposes only and does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shal
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... Feb. 27, 2015  Finesse expands office in ... announced the expansion of its operations in ... mid-March and access for customers is expected shortly afterward. ... located adjacent to the current office, the new premises ... team and allow Finesse to bring on more service ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3New Finesse Office in United Kingdom 2
... May 11 The DNA Medicine Institute announced today that ... the Bill & Melinda Gates Foundation.  The grant will support an innovative ... titled "Optomagnetic Finger Scanner for Malaria." , ... Dr. Chan,s project is one of 78 grants announced by ...
... CHANGCHUN, China and LOS ... Inc. (OTC Bulletin Board: CYXN) (the "Company" or,"China Yongxin"), one ... today,announced that on March 31st, 2010 , the Company,s ... as one of the,qualified pharmaceuticals distributors for Jilin ...
Cached Medicine Technology:DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 2China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 3
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... BELLEVUE, Wash., Sept. 11 The Citizens,Committee for the ... with,Oklahoma Sen. Tom Coburn that there is a serious ... Suicide Prevention Act -- that could,ultimately prevent military veterans ... defend., The problem, as pointed out by Sen. ...
... Thanks to a $1.6 million grant from the Welch ... launching a new initiative to develop innovative computational and ... drugs and molecular tools for biomedical science. , The ... Gulf Coast Consortium for Chemical Genomics (GCC CG) to ...
... with the breast cancer susceptibility gene BRCA1 often remove ... they believe fuels cancer growth. Yet they also know ... ovarian cancer that might develop. That paradox has led ... involved in cancer development and whether removal of ovaries ...
... Inc. (Pink Sheets: MSITF) wishes to announce that it has,completed ... Hepatitis C,test kit in Europe. Completion of this testing will ... EU approval would allow the Company to expand its ... It is anticipated that,when EU approval is received that it ...
... Sept. 11 Responding to a lawsuit by ... national medical,licensing examination, the National Board of Medical ... the needs of breastfeeding mothers as well as,other ... first priority for this test, accepted as evidence ...
... treatment, reseachers say , TUESDAY, Sept. 11 (HealthDay News) ... believe they may have found the disease,s genetic on/off ... to the development of better treatments, the team said. ... mouse model for schizophrenia by inserting the mutant Disrupted-In-Schizophrenia ...
Cached Medicine News:Health News:CCRKBA Backs Sen. Coburn's Opposition to Tenets of H.R. 327 2Health News:Welch Foundation gives $1.6 million for drug discovery research 2Health News:Welch Foundation gives $1.6 million for drug discovery research 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Medical Services International Inc. Completes Testing for European Union (EU) Application 2Health News:Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test 2Health News:Schizophrenia Gene May Have On/Off Switch 2
... steps any hospital or health system can ... most effective tools available for physicians and ... documentation and electronic medical record (EMR) system, ... goal. In fact, its the most reliable ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... clinician documentation and electronic medical record (EMR) ... specific needs of intensive care units and ... clinical functionality has secured its place as ... critical care, and its the most reliable ...
... itself to over 2,000 medical clinics nation ... user in mind, ChartingPlus relies heavily on ... features to improve documentation quality and increase ... Our medical content is specific to your ...
Medicine Products: